## STE: STERIS plc (Ireland) - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.84 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($252.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Vinva Investment Management Ltd Has $1.60 Million Position in STERIS plc $STE**
- Source: MarketBeat | 20251130T135131 | Bullish | Relevance: 99%
- Vinva Investment Management Ltd significantly increased its stake in STERIS plc, now holding 6,690 shares valued at approximately $1.60 million. Other major institutional investors like Vanguard and UBS also hold substantial positions as institutional ownership stands at 94.69%. STERIS exceeded quarterly earnings expectations and provided strong FY 2026 guidance, while analysts maintain a "Moderate Buy" rating with an average price target of $273.50.

**2. Choreo LLC Sells 3,076 Shares of STERIS plc $STE**
- Source: MarketBeat | 20251201T093342 | Somewhat-Bullish | Relevance: 98%
- Choreo LLC reduced its stake in STERIS plc by 47.7%, selling 3,076 shares and leaving them with 3,369 shares valued at approximately $809,000. STERIS plc reported strong quarterly earnings, beating analyst estimates with EPS of $2.47 and revenue of $1.46 billion, and provided positive FY2026 EPS guidance. Institutional investors hold a significant 94.69% of the company, while insiders have recently sold a substantial number of shares.

**3. STERIS (STE): Evaluating Valuation After Recent Share Price Surge**
- Source: Sahm | 20251130T130933 | Somewhat-Bullish | Relevance: 98%
- STERIS (STE) shares have surged nearly 13% in the past month and 31.5% year-to-date, reflecting strong investor interest in its infection prevention solutions and steady revenue growth. While a common narrative suggests the stock is 5.4% undervalued with a fair value of $281.63, its high P/E ratio of 37.9x compared to peers and industry averages indicates that significant future growth might already be priced in, posing a crucial question for investors regarding further upside potential.

**4. Zacks Research Issues Negative Forecast for STERIS Earnings**
- Source: MarketBeat | 20251201T063333 | Neutral | Relevance: 98%
- Zacks Research has lowered its Q3 2026 EPS estimate for STERIS to $2.53 and projects FY2026 EPS of $10.20, while providing forecasts through Q1 2028. Despite this, STERIS recently beat earnings expectations with $2.47 EPS and $1.46B revenue, reiterating its FY2026 guidance. The report also highlights notable insider selling and details past analyst ratings and stock performance metrics.

**5. STERIS plc $STE Shares Acquired by Neuberger Berman Group LLC**
- Source: MarketBeat | 20251130T122158 | Somewhat-Bullish | Relevance: 98%
- Neuberger Berman Group LLC significantly increased its stake in STERIS plc (NYSE:STE) by 64.7% in the second quarter of 2025, now owning 19,416 shares valued at $4.66 million. Institutional investors collectively own 94.69% of STERIS stock. The company reported strong Q2 earnings, beating consensus estimates, and provided positive FY 2026 guidance, while analysts maintain a "Moderate Buy" rating with an average price target of $273.50.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.84 elevated, pricing in significant growth expectations. Forward P/E 23.6x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.5B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.84 |
| Forward P/E | 23.6 |
| Current P/E | 25.8 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.5% to -1.6% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). Underperforming sector by 3.0pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.65% (CS: 32) | Neutral |
| RSI_14 | 59.9 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.109x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $262.89
- **Stop Loss:** $252.31 (4.0% risk)
- **Target:** $273.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 70
- **Position Value:** $18,402.30
- **Portfolio %:** 18.40%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*